Imaplix (Apremilast)

• Imaplix (apremilast) acts on the phosphodiesterase‑4 pathway to reduce inflammatory activity in skin and joint disease.
• Psoriasis: improves skin lesions by lowering keratinocyte proliferation and reducing erythema, scaling and plaque thickness through modulation of inflammatory mediators.
• Psoriatic arthritis: diminishes joint inflammation, pain and stiffness, leading to better mobility and functional capacity in patients with active disease.

• Apremilast selectively inhibits the intracellular enzyme phosphodiesterase‑4 (PDE4), resulting in increased cyclic adenosine monophosphate (cAMP) levels within immune cells. Elevated cAMP down‑regulates the production of pro‑inflammatory cytokines such as TNF‑α, IL‑17 and IL‑23, while enhancing anti‑inflammatory mediators, thereby modulating the immune response involved in psoriasis and psoriatic arthritis. The shift in cytokine balance leads to reduced recruitment of inflammatory cells to skin and joint tissues, contributing to clinical improvement.

Imaplix may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach, often transient.
• Diarrhea: loose stools that may improve with continued therapy.
• Headache: mild to moderate intensity, usually resolves over time.
• Upper respiratory tract infection: symptoms such as sore throat or nasal congestion.

Serious or Rare Side Effects

• Depression or suicidal thoughts: new or worsening mood changes require immediate evaluation.
• Severe allergic reaction (anaphylaxis): signs include rash, swelling, difficulty breathing.
• Pancreatitis: abdominal pain, nausea, and elevated enzymes warrant urgent medical attention.

• When prescribing Imaplix, clinicians should consider several precautionary measures to ensure patient safety.
• Monitor for depression: patients should be screened for mood changes and suicidal ideation.
• Assess liver function: baseline and periodic liver enzyme tests are recommended.
• Evaluate renal function: dose adjustment may be needed in severe renal impairment.
• Avoid in uncontrolled infection: defer treatment during active serious infections.
• Use caution in cardiovascular disease: monitor blood pressure and heart rate.
• Store at room temperature: keep in original packaging, protect from moisture and heat.

Apremilast can interact with other medicines, affecting its metabolism or therapeutic effect.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase apremilast exposure.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce apremilast efficacy.

Moderate Interactions (Monitor Closely)

• Warfarin: may require more frequent INR monitoring.
• Oral contraceptives: apremilast may reduce hormonal effectiveness.
• Digoxin: monitor serum levels for potential changes.